TLDR SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.
The study demonstrated that Selective Androgen Receptor Modulators (SARMs), such as GTx-027 and GTx-024, significantly inhibited the growth and proliferation of triple-negative breast cancer (TNBC) cells both in vitro and in vivo. SARMs reduced tumor growth by over 75% and tumor weight by more than 50% without toxicity, and they also counteracted cancer-associated cachexia. SARMs suppressed key genes and pathways involved in cancer metastasis, particularly IL6 and MMP13, which are crucial for epithelial-mesenchymal stem cell interactions. These findings suggested that SARMs could be a promising therapeutic strategy for managing TNBC by targeting specific signaling mechanisms involved in cancer cell proliferation and metastasis.
306 citations,
August 2011 in “Journal of cachexia, sarcopenia and muscle” Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
20 citations,
September 2005 in “Endocrinology” Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.
21 citations,
March 2019 in “Critical Reviews in Clinical Laboratory Sciences” The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.
306 citations,
August 2011 in “Journal of cachexia, sarcopenia and muscle” Enobosarm significantly increased muscle mass and improved physical function in elderly men and postmenopausal women without serious side effects.
2 citations,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
77 citations,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
11 citations,
August 2009 in “Expert Opinion on Drug Discovery” We need better ways to test and understand SARMs to make safer and more effective treatments.
